- Home
- CYN vs REVB Comparison
CYN vs REVB Comparison
Compare CYN & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- REVB
- Stock Information
- Founded
- CYN 2013
- REVB 2020
- Country
- CYN United States
- REVB United States
- Employees
- CYN N/A
- REVB N/A
- Industry
- CYN EDP Services
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- REVB Health Care
- Exchange
- CYN Nasdaq
- REVB Nasdaq
- Market Cap
- CYN N/A
- REVB 2.8M
- IPO Year
- CYN 2021
- REVB N/A
- Fundamental
- Price
- CYN $4.36
- REVB $3.10
- Analyst Decision
- CYN
- REVB
- Analyst Count
- CYN 0
- REVB 0
- Target Price
- CYN N/A
- REVB N/A
- AVG Volume (30 Days)
- CYN 47.5K
- REVB 54.4K
- Earning Date
- CYN 05-07-2025
- REVB 05-13-2025
- Dividend Yield
- CYN N/A
- REVB N/A
- EPS Growth
- CYN N/A
- REVB N/A
- EPS
- CYN N/A
- REVB N/A
- Revenue
- CYN $409,777.00
- REVB N/A
- Revenue This Year
- CYN $1,162.03
- REVB N/A
- Revenue Next Year
- CYN $427.83
- REVB N/A
- P/E Ratio
- CYN N/A
- REVB N/A
- Revenue Growth
- CYN N/A
- REVB N/A
- 52 Week Low
- CYN $3.62
- REVB $2.36
- 52 Week High
- CYN $2,700.00
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- CYN 35.22
- REVB 51.92
- Support Level
- CYN $5.05
- REVB $2.79
- Resistance Level
- CYN $5.49
- REVB $3.09
- Average True Range (ATR)
- CYN 0.41
- REVB 0.24
- MACD
- CYN 0.46
- REVB 0.02
- Stochastic Oscillator
- CYN 32.39
- REVB 38.82
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).